You are here

Home » People » Faculty
Photo

Erkki Ruoslahti

Distinguished Professor

Contact Information

Phone: (805) 893-5327
Email: ruoslahti@sanfordburnham.org
Office: 3110 Bio II
Website: Ruoslahti Laboratory

Address

Molecular, Cellular, and Developmental Biology
University of California, Santa Barbara
Santa Barbara, CA 93106-9625

Bio

Dr. Erkki Ruoslahti is Distinguished Professor at the Center for Nanomedicine, Sanford-Burnham Medical Research Institute at UCSB. He received his M.D. and Ph.D. degrees from the University of Helsinki, Finland. Having held various academic positions in Finland and in the US, he joined Sanford-Burnham in 1979 and served as President of the institute from 1989 to 2002.

Ruoslahti’s main scientific contributions are in the field of cell adhesion. He was one of the discoverers of fibronectin. His laboratory discovered in fibronectin the RGD cell attachment sequence and isolated cellular RGD receptors, now known as integrins.

Research

The Ruoslahti laboratory currently studies peptides that home to specific targets in the body, such as tumors and atherosclerotic plaques. These peptides, which usually bind to receptors in the vessels of the target tissue, can be used to selectively deliver diagnostic probes and drugs to the target. The latest development is the discovery of homing peptides with tumor-penetrating properties that can enhance tumor accumulation of anti-cancer drugs, even when co-administered with the drug without chemical coupling. New anti-cancer therapies that use these peptides for targeted delivery of to improve the activity and reduce the side effects of existing anti-cancer drugs and to design new nanoparticle-based drugs.

Selected Publications

  • Ruoslahti, E. RGD story: a personal account. A Landmark Essay. Matrix Biology. 22: 459-465 (2003).
  • Teesalu, T., Sugahara K., Kotamraju, V.R., Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Nat. Acad. Sci. USA. 106:16157-16162 (2009) PMCID: PMC2752543
  • Sugahara., K.N., Teesalu T, Karmali P, Agemy L., Kotamraju V.R, Girard O.M., Mattrey, R.F. and Ruoslahti E. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell, 16: 510-520, 2009. PMCID: 2791543.
  • Ji-Ho Park J-H., Maltzahn Gv, Xuc MJ, Fogal V., Kotamraju V.R., Ruoslahti, E., Bhatia S.N., and Sailor, M.J., Cooperative nanomaterial system to sensitize, target, and treat tumors. PNAS, 107:981-986, 2010 PMCID: PMC2824295
  • Ruoslahti, E., Bhatia SN., Sailor, MJ. Targeting of Drugs and Nanoparticles to Tumors. J Cell Bio. 188:759-768 (2010) PMCID: PMC2845077
  • Sugahara, K.N., Teesalu, T, Karmali, P.P., Kotamraju V.R., Agemy, L. Greenwald, D.R. and Ruoslahti E. Co-administration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs. Science, 328: 1031-1035 (2010). PMCID: PMC2881692
  • Agemy, L., Sugahara, K.N., Kotamraju V.R., Gujraty K., Girard, O.M., Kono Y, Mattrey R.F., Park J-H, Sailor M.J., Jimenez A.I., Cativiela C, Zanuy D, Sayago F.J., Aleman C, Nussinov R. and Ruoslahti E. Nanoparticle-induced vascular blockade in human prostate cancer. Blood 116: 2847-2856 (2010).
  • Fraikin, J-L., Teesalu, T., McKenney, C.M., Ruoslahti E., and Cleland, A.N. A high-throughput label-free nanoparticle analyser. Nature Nanotech. 6:308-313 (2011). (PMCID in process).
  • Hamzah, J., Kotamraju, V.R., Seo, J.W., Agemy, L., Fogal, V., Mahakian, L.M., Peters, D., Roth, L., Gagnon, M.K.J., Ferrara, K.W., and Ruoslahti, E. Specific penetration and accumulation of a homing peptide within atheroschlerotic plaques of ApoE deficient mice. Proc. Natl. Acad. Sci., USA. 108: 7154-7159 (2011) PMCID:PMC3084060.
  • Agemy, L., Friedmann-Morvinski, D., Kotamraju V.R., Roth, L., Sugahara K.N., , Girard,O.M., Robert Mattrey, R.F., Inder M. Verma I.M., and Erkki Ruoslahti E. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc. Natl. Acad. Sci., USA 2011 108:17450-17455 PMCID: PMC3198371